Specific chemotherapy of Chagas disease: a comparison between the response in patients and experimental animals inoculated with the same strains

Sonia G. Andrade, Anis Rassi, Juracy B. Magalhaes, Francisco Ferriolli Filho and Alexandre O. Luquetti

Abstract

Eleven strains of *Trypanosoma cruzi* were isolated from patients with Chagas disease in central Brazil by xenodiagnosis and inoculation into newborn mice. Biological characterization and isoenzyme analysis showed that 6 strains were type II (zymodeme 2) and 5 were type III (zymodeme 1). Patients were treated with benznidazole or benznidazole plus nifurtimox. Mice infected with each isolated strain were treated for comparison with the results obtained in the respective patient. Evaluation of cure of the patients was based on the indirect immunofluorescence test, complement fixation reaction and xenodiagnosis. For the mice, haemoculture, indirect immunofluorescence testing, xenodiagnosis and inoculation of blood into newborn mice were used. Tests were performed 3–6 months after the end of treatment. The cure rate was 66–100% in mice infected with type II strains and 0–9% in those infected with type III strains. The correlation between treatment results in patients and mice was 81.8% (9 of 11 cases). Type II strains were more susceptible to treatment, in contrast to type III strains which yielded the majority of therapeutic failures.

Introduction

Treatment of patients with acute and chronic Chagas disease with the drugs in current clinical use (benznidazole and nifurtimox) has yielded disparate results (Boatin et al., 1979; Frata et al., 1975). Discrepancies are even greater when therapeutic trials from different geographical areas are compared. Ceresola et al. (1974) in Argentina claimed an 81% cure rate with nifurtimox in acute infections. In Brazil the reported rates with the Minas Gerais strain were 53.8% (Cancado, 1985) and 51.3% (1988) obtained 80% cure in Argentina, while in Brazil the rates were 53.8% (Cancado, 1985) and 51.3% (Rassi, 1982).

One of the factors contributing to these different results could be the parasite strain together with the biological characteristics of the patient. Several strains of *Trypanosoma cruzi* were isolated from patients living in central Brazil and were characterized to strain types according to established criteria (Andrade et al., 1985). The present investigation was an attempt to compare clinical and experimental observations. Several strains of *Trypanosoma cruzi* were isolated from patients living in central Brazil and were characterized to strain types according to established criteria (Andrade et al., 1985; WHO, 1986). Results of treatment in the patient and in mice infected with the corresponding *T. cruzi* strain were compared, in the hope that this would help to clarify the role of parasite strain in susceptibility and resistance to drug treatment.

Materials and Methods

The area in central Brazil from which the 11 strains of *T. cruzi* were isolated has been described by Luquetti et al. (1986). Six cases were from Montalvania, north-west Minas Gerais state, 4 came from Carinhanga, Bahia and one from A. Dourados, close to the eastern border of Goias state.

### Table. Correlation between the clinical and experimental response to chemotherapy of Chagas disease with benznidazole and nifurtimox

<table>
<thead>
<tr>
<th>Case no.</th>
<th>Age (years)</th>
<th>Sex</th>
<th>Clinical form</th>
<th>Clinical chemotherapy</th>
<th>Experimental data</th>
<th>Experimental chemotherapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>13</td>
<td>Female</td>
<td>Acute</td>
<td>10 mg/kg body weight</td>
<td>60</td>
<td>Resistant 1-MONT II Z2</td>
</tr>
<tr>
<td>2</td>
<td>42</td>
<td>Male</td>
<td>Chronic</td>
<td>8 mg/kg body weight</td>
<td>60</td>
<td>Resistant 4-MONT III Z2</td>
</tr>
<tr>
<td>3</td>
<td>40</td>
<td>Male</td>
<td>Acute</td>
<td>5 mg/kg body weight</td>
<td>60</td>
<td>Resistant 5-MONT II Z2</td>
</tr>
<tr>
<td>4</td>
<td>35</td>
<td>Female</td>
<td>Acute</td>
<td>6 mg/kg body weight</td>
<td>60</td>
<td>Cured 9-MONT III Z1</td>
</tr>
<tr>
<td>5</td>
<td>5</td>
<td>Female</td>
<td>Acute</td>
<td>6 mg/kg body weight</td>
<td>60</td>
<td>Cured 12-MONT II Z2</td>
</tr>
<tr>
<td>6</td>
<td>13</td>
<td>Male</td>
<td>Acute</td>
<td>10 mg/kg body weight</td>
<td>60</td>
<td>Cured 15-MONT II Z2</td>
</tr>
<tr>
<td>7</td>
<td>12</td>
<td>Male</td>
<td>Acute</td>
<td>10 mg/kg body weight</td>
<td>60</td>
<td>Cured 20-MONT II Z2</td>
</tr>
<tr>
<td>8</td>
<td>32</td>
<td>Male</td>
<td>Acute</td>
<td>5 mg/kg body weight</td>
<td>60</td>
<td>Cured 22-MONT II Z2</td>
</tr>
<tr>
<td>9</td>
<td>6</td>
<td>Female</td>
<td>Chronic</td>
<td>6 mg/kg body weight</td>
<td>60</td>
<td>Cured 24-MONT II Z2</td>
</tr>
<tr>
<td>10</td>
<td>11</td>
<td>Female</td>
<td>Acute</td>
<td>9 mg/kg body weight</td>
<td>60</td>
<td>Cured 25-MONT III Z1</td>
</tr>
<tr>
<td>11</td>
<td>13</td>
<td>Female</td>
<td>Acute</td>
<td>6 mg/kg body weight</td>
<td>60</td>
<td>Resistant 1-CAR III Z1</td>
</tr>
</tbody>
</table>

*Cases 1, 5, 6, 7, 8, 10 from Montalvania (MG); cases 3, 4, 9, 11 from Carinhanga (BA); case 2 from A. Dourados (MG).*

*All patients treated with benznidazole; cases 2 and 3 also treated with nifurtimox. Case 2: first treatment with nifurtimox, 8 mg/kg body weight/d for 60 d, not cured. Case 3: Second treatment with nifurtimox, 8 mg/kg body weight/d for 75 d, result inconclusive (serological reactions with variable results and negative xenodiagnosis).*

*Strains 4, 11, 11 isolated from previously treated patient (case 2).*

(1988) obtained 80% cure in Argentina, while in Brazil the rates were 53.8% (Cancado, 1985) and 51.3% (Rassi, 1982).

Description of clinical cases. General clinical data are given in the Table. Nine patients had acute Chagas disease (6 females and 3 males) and 2 had chronic infections (indeterminate form). Parasites were detected by direct examination of peripheral blood in all acute cases and by xenodiagnosis in the chronic cases.

Clinical chemotherapy. Nine patients were treated solely with benznidazole. Two other patients received nifurtimox either preceding (case 2) or following (case 3) treatment with benznidazole. Benznidazole (N-benzyl-2- (2-nitro-imidazol-1-yl)acetamide) was given orally in doses of 5–10 mg/kg body weight/d divided into 2 or 3 doses, for 60 d. Nifurtimox (tetrahydro-3-methyl-4-(nitrofuryl)deanemino-1, 4-thiazine-1,1-dioxide) was given orally in doses of 8–8.7 mg/kg body weight/d for 60 or 75 d (see Table).
patients were considered cured when both serological tests remained persistently negative and xenodiagnosis, performed monthly and repeated 25 or more times, was consistently negative. Xenodiagnosis was performed with 40 third-stage nymphs of Triatominae, which were examined 30 and 60 d after blood feeding.

**Experimental procedures.** *T. cruzi* was isolated from reduviid nymphs which had been used for xenodiagnosis and the strains were characterized by morpho-biological features (ANDRADE, 1985) and isoenzyme electrophoretic patterns (MILES, 1980; ANDRADE et al., 1983). Briefly, morpho-biological characterization consisted of the observation of parasitaemia curves, morphology of blood forms of the parasite, virulence, tissue tropism, and histopathology during experimental infections of mice. Isoenzyme patterns were determined from extracts of parasites cultured in Warren’s medium. The following enzymes were studied: aspartate aminotransferase (E.C.2.6.1.1., ASAT), alanine aminotransferase (E.C.2.6.1.2., ALAT), phosphoglucosemutase (E.C.2.7.5.1., PGM) and glucose phosphate isomerase (E.C.5.3.1.9., GPI).

**Experimental chemotherapy.** Each isolated strain was inoculated to a group of 70 mice each weighing 10–12 g. Each mouse received 1×10^6 blood forms. Thirty days after infection, mice were treated with benznidazole, 30 with nifurtimox, and 10 were left as untreated controls. Dosage schedules for the mice were based upon that used by HABERKORN & GONNET, (1972), who established the equivalence between doses of 15 or 10 mg/kg body weight for adult men and doses of 180 or 120 mg/kg body weight for mice. An initial daily dose of 200 mg/kg of nifurtimox was given for 4 d, followed by 50 mg/kg for 90 d. Benznidazole was given on 5 d per week, at 100 mg/kg body weight, for 90 d, according to RICHEL & RAALFOUT (1980).

**Criteria of cure.** Xenodiagnosis with 5th stage *R. prolixus* nymphs, submucosal injection of blood into newborn mice and histopathological examination were performed 3–6 months after treatment. The same tests were made on the control mice. IIFT was performed with *T. cruzi* culture forms as antigen and anti-mouse fluorescein-conjugated y-globulin (dilution 1:80). Titers >1:10 were considered to be positive.

**Results**

**Experimental results**

Six of the isolated *T. cruzi* strains belonged to type II (zymodeme 2) and 5 to type III strains (zymodeme 1) (Table). Mice infected with most type II strains had a cure rate of 66–100% when treated with benznidazole and nifurtimox (Table). One strain (4-MONT), from a previously treated strain, was left as untreated controls. Dosage schedules for the mice were based upon that used by HABERKORN & GONNET (1972), who established the equivalence between doses of 15 or 10 mg/kg body weight for adult men and doses of 180 or 120 mg/kg body weight for mice. An initial daily dose of 200 mg/kg of nifurtimox was given for 4 d, followed by 50 mg/kg for 90 d. Benznidazole was given on 5 d per week, at 100 mg/kg body weight, for 90 d, according to RICHEL & RAALFOUT (1980).

**Assessment of cure** was based on the parasitological tests, because the IIFT remained positive with all animals.

**Clinical results**

Seven of the 11 patients treated with benznidazole were considered cured, with both xenodiagnosis and serological tests consistently negative. Therapeutic failures were observed in 4 patients, 2 of whom were treated with both drugs (Table).

**Comparison of clinical and experimental results**

The results of clinical and experimental chemotherapy were in agreement in 9 of the 11 cases (82%). Five of the 6 patients harbouring type II strains were cured, and mice infected with type II strains had a high cure rate. Four species were used, according to availability: *Rhodius prolixus*, *Triatoma brasiliensis*, *T. infestans* and *Dipetalogaster maxima*.

Received 14 January 1992; revised 24 March 1992; accepted for publication 24 March 1992

---

**Announcement**

**President's Fund**

Council has decided to launch an appeal to raise money with the aim of establishing a fund to sponsor prospective Fellows from developing countries, who are at present unable to become Fellows of the Society because of their country's fiscal rules which prevent them from paying.

The fund will be known as The President's Fund for Overseas Fellows in Developing Countries and will be used to sponsor deserving candidates for full Fellowship of the Society for a trial period of three years.

The Society will make an initial donation of £2000 from its reserves to launch the Fund, and will then rely on donations from Fellows (including Honorary and Life Fellows) of the Society, and other, perhaps commercial, sources to build up the fund.

Any Fellows willing to donate to the President’s Fund in order to help sponsor a Fellow from a developing country, are asked to write to Manson House.